Heliyon · 2024 · 23 citations · 56 references
MedicineNeurologyPharmacologyDementiaNeurodegenerationNeuropharmacologyAlzheimer DiseaseBiomarkers Of NeurodegenerationCellular SenescenceDementia BiomarkersNeurodegenerative DiseasesNeuroinflammationAge-related Neurodegenerative MechanismsAge-related NeuroinflammationAlzheimer Disease ProgressionBiomarkersSenescenceSenescent Cell AccumulationSenolytic TherapyTransgenic Rodent Models
Alzheimer's disease (AD) is the most common global dementia and is universally fatal. Most late-stage AD disease-modifying therapies are intravenous and target amyloid beta (Aβ), with only modest effects on disease progression: there remains a high unmet need for convenient, safe, and effective therapeutics. Senescent cells (SC) and the senescence-associated secretory phenotype (SASP) drive AD pathology and increase with AD severity. Preclinical senolytic studies have shown improvements in neuroinflammation, tau, Aβ, and CNS damage; most were conducted in transgenic rodent models with uncertain human translational relevance. In this study, aged cynomolgus monkeys had significant elevation of biomarkers of senescence, SASP, and neurological damage. Intermittent treatment with the senolytic navitoclax induced modest reversible thrombocytopenia; no serious drug-related toxicity was noted. Navitoclax reduced several senescence and SASP biomarkers, with CSF concentrations sufficient for senolysis. Finally, navitoclax reduced TSPO-PET frontal cortex binding and showed trends of improvement in CSF biomarkers of neuroinflammation, neuronal damage, and synaptic dysfunction. Overall, navitoclax administration was safe and well tolerated in aged monkeys, inducing trends of biomarker changes relevant to human neurodegenerative disease.
56
R: A Language and Environment for Statistical Computing
R Core Team · 2000 · 353K citations · Full text
Natural Sciences, Computer Science, Statistical Computing +10
Lecanemab in Early Alzheimer’s Disease
Christopher H. van Dyck, Chad J. Swanson, Paul Aisen et al. · New England Journal of Medicine · 2022 · 5.2K citations · Full text
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Darren J. Baker, Tobias Wijshake, Tamar Tchkonia et al. · Nature · 2011 · 3.6K citations · Full text